IMMP - Immutep gets patents in Japan South Korea linked to immunotherapy eftilagimod

• Immutep ( NASDAQ: IMMP ) said it was granted two patents (numbers 7160345 and 10-2441425) by the Japanese Patent Office and South Korean Patent Office, respectively.
• The patents titled 'Combined Preparations for the Treatment of Cancer' protects intellectual property related to combination preparations consisting of the company's immunotherapy candidate eftilagimod alpha and a chemotherapy agent which is oxaliplatin, carboplatin, or topotecan, Immutep noted.
• The combination type patent claims are written in multiple formats to maximize the scope of protection and both patents expire on Dec. 19, 2034, according to the company.
• "These new patents are notable because this family of patents protects a component of the triple combination therapy being evaluated in our INSIGHT-003 clinical trial," said Immutep CEO Marc Voigt.

For further details see: